Free Trial

Novartis (NVS) Competitors

Novartis logo
$128.01 +1.38 (+1.09%)
As of 12:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NVS vs. NVO, AZN, SNY, GSK, TAK, ARGX, ONC, INSM, BNTX, and TEVA

Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

Novartis vs. Its Competitors

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$42.12B6.02$14.64B$3.6415.60
Novartis$50.32B5.37$11.94B$6.8718.63

Novo Nordisk A/S presently has a consensus target price of $81.00, indicating a potential upside of 42.62%. Novartis has a consensus target price of $123.50, indicating a potential downside of 3.53%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Novartis
2 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.10

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.4%. Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays out 22.5% of its earnings in the form of a dividend. Novartis pays out 37.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Novo Nordisk A/S had 39 more articles in the media than Novartis. MarketBeat recorded 64 mentions for Novo Nordisk A/S and 25 mentions for Novartis. Novartis' average media sentiment score of 1.55 beat Novo Nordisk A/S's score of 0.61 indicating that Novartis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
29 Very Positive mention(s)
2 Positive mention(s)
26 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Positive
Novartis
23 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Novo Nordisk A/S has a net margin of 35.60% compared to Novartis' net margin of 25.64%. Novo Nordisk A/S's return on equity of 78.64% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S35.60% 78.64% 24.51%
Novartis 25.64%41.08%16.83%

Summary

Novo Nordisk A/S beats Novartis on 12 of the 19 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVS vs. The Competition

MetricNovartisLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$270.41B$254.48B$5.75B$21.15B
Dividend Yield2.05%2.68%6.66%3.50%
P/E Ratio18.6330.8082.2029.04
Price / Sales5.374.96531.0548.03
Price / Cash11.8313.6125.7018.29
Price / Book6.437.6410.475.29
Net Income$11.94B$8.49B$3.28B$997.87M
7 Day Performance0.83%1.00%-0.17%-0.63%
1 Month Performance11.08%7.38%10.19%6.33%
1 Year Performance8.07%-8.84%46.75%13.76%

Novartis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVS
Novartis
2.688 of 5 stars
$128.02
+1.1%
$123.50
-3.5%
+4.7%$270.41B$50.32B18.6375,883News Coverage
Positive News
NVO
Novo Nordisk A/S
4.3499 of 5 stars
$55.75
-1.2%
$81.00
+45.3%
-59.5%$249.32B$42.12B15.3454,400Trending News
AZN
AstraZeneca
2.59 of 5 stars
$79.74
-0.2%
$86.00
+7.9%
-8.5%$247.44B$54.07B29.9983,500Positive News
SNY
Sanofi
3.2653 of 5 stars
$49.77
-0.7%
$62.00
+24.6%
-11.9%$122.33B$44.46B11.9891,600Positive News
Analyst Upgrade
Short Interest ↑
GSK
GSK
2.508 of 5 stars
$39.66
-0.6%
$37.38
-5.8%
-11.4%$80.81B$40.10B18.3790,100Dividend Cut
TAK
Takeda Pharmaceutical
2.457 of 5 stars
$14.96
+0.6%
N/A+1.8%$47.62B$30.09B49.8847,455
ARGX
argenx
3.9972 of 5 stars
$703.69
-0.6%
$766.50
+8.9%
+36.6%$43.02B$3.05B36.041,599Analyst Forecast
ONC
BeOne Medicines
0.8016 of 5 stars
$299.23
-0.3%
$330.89
+10.6%
N/A$32.80B$3.81B-172.9611,000
INSM
Insmed
3.6739 of 5 stars
$135.90
+1.0%
$132.57
-2.4%
+90.0%$28.76B$363.71M-23.831,271Positive News
Analyst Forecast
BNTX
BioNTech
2.0706 of 5 stars
$102.45
-0.5%
$135.80
+32.6%
+14.1%$24.59B$2.98B-64.196,772Positive News
TEVA
Teva Pharmaceutical Industries
3.6731 of 5 stars
$17.90
-0.9%
$24.71
+38.1%
-0.5%$20.58B$16.63B-112.1636,830News Coverage
Positive News

Related Companies and Tools


This page (NYSE:NVS) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners